Scopus Biopharma Buy Hold or Sell Recommendation
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding Scopus Biopharma is 'Not Rated'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Scopus Biopharma given historical horizon and risk tolerance towards Scopus Biopharma. When Macroaxis issues a 'buy' or 'sell' recommendation for Scopus Biopharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. Note, we conduct extensive research on individual companies such as Scopus and provide practical buy, sell, or hold advice based on investors' constraints. Scopus Biopharma. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Scopus |
Execute Scopus Biopharma Buy or Sell Advice
The Scopus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Scopus Biopharma. Macroaxis does not own or have any residual interests in Scopus Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Scopus Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Scopus Biopharma Trading Alerts and Improvement Suggestions
| Scopus Biopharma is not yet fully synchronised with the market data | |
| Scopus Biopharma has some characteristics of a very speculative penny stock | |
| Scopus Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scopus Biopharma currently holds about 1.16 M in cash with (11.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. | |
| Roughly 51.0% of Scopus Biopharma outstanding shares are owned by corporate insiders |
Scopus Biopharma current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Scopus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Scopus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Scopus Biopharma Returns Distribution Density
The distribution of Scopus Biopharma's historical returns is an attempt to chart the uncertainty of Scopus Biopharma's future price movements. The chart of the probability distribution of Scopus Biopharma daily returns describes the distribution of returns around its average expected value. We use Scopus Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Scopus Biopharma returns is essential to provide solid investment advice for Scopus Biopharma.
| Mean Return | 0.26 | Value At Risk | -24.69 | Potential Upside | 35.42 | Standard Deviation | 18.88 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Scopus Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Scopus Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Scopus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.0909 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.11 | |||
| Day Typical Price | 0.1 | |||
| Market Facilitation Index | 0.01 | |||
| Price Action Indicator | (0.01) | |||
| Relative Strength Index | 47.48 |
About Scopus Biopharma Buy or Sell Advice
When is the right time to buy or sell Scopus Biopharma? Buying financial instruments such as Scopus OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Scopus Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Materials ETFs Thematic Idea Now
Materials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Materials ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Materials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |